Nov. 20, 2015, 7:49 AM
- With the aim of enhancing its presence in the home care market, C.R. Bard (NYSE:BCR) acquires Liberator Medical Holdings (NYSEMKT:LBMH), a direct-to-consumer distributor of Durable Medical Equipment (DME), for $3.35 per share (~$181M).
- Liberator sells general medical supplies including urological catheters, ostomy products, mastectomy fashions, diabetic supplies and a modest amount of Bard's products.
- The transaction, which will add ~$70M to Bard's top line and be slightly accretive to non-GAAP EPS in 2016, should close in Q1. Starting in 2017, the acquisition will add between five and ten cents to non-GAAP cash EPS.
- LBMH is up 25% premarket.
Sep. 4, 2013, 7:49 AM
- C.R. Bard (BCR) will acquire Rochester Medical (ROCM) for $20/ share.
- The deal "greatly enhances BCR's position in a $930 million global urology homecare market," management says. ROCM had net sales of $61.68M last year. (PR)
- It's a good day to be an ROCM shareholder — the purchase price represents a nearly 45% premium from Tuesday's close.
- ROCM +43.7% premarket
- Last month: BCR acquires Medafor for $200M
Aug. 19, 2013, 8:39 AM
- C.R. Bard (BCR) will acquire Medafor for $200M up-front and $80M in revenue-based milestone payments over the next two years.
- The deal is expected to add 1% to FY14 revenue growth and will be "a few cents dilutive" to adjusted EPS this year. (PR)
Jun. 28, 2013, 11:29 AM
C.R. Bard (BCR +1%) say sold certain assets of its Electrophysiology division to Boston Scientific (BSX +1.6%) for $275M in cash. BCR's Electrophysiology division manufactures and markets medical equipment, catheters and accessories used in cardiac electrophysiology procedures. Annual net sales linked to the divested assets totaled aoound $111M in 2012. The company expects the sale to be about $0.05 dilutive to 2013 EPS and immaterial to 2014 guidance previously provided.| Jun. 28, 2013, 11:29 AM
Dec. 20, 2011, 5:03 PM
C.R. Bard (BCR) acquires Lutonix - a privately-held medical device developer currently conducting an FDA-approved investigational device exemption trial using drug-coated balloons for the treatment of peripheral arterial disease - for $225M, plus an additional $100M upon PMA approval of the device.| Dec. 20, 2011, 5:03 PM
Oct. 25, 2011, 4:43 PMC.R. Bard (BCR): Q3 EPS of $1.62 beats by $0.02. Revenue of $719.2M (+6% Y/Y) misses by $6M. The medical technology provider also says it will buy privately-held Medivance for $250M. (earnings PR; acquisition PR) | Oct. 25, 2011, 4:43 PM